Contents

Issue 116 • March 2022

In association with

Cutting the carbon footprint of pharma’s supply chain

The pharmaceutical industry must reduce the carbon emissions associated with getting drugs to patients – but how?

IN DEPTH

Uneven supply patterns hinder US rollout of Covid-19 antivirals

Comment

Psychedelics: The next trip for CMOs

Briefing

Industry news

Pharma industry briefing

Covid-19 briefing

Comment

Psychedelics: The next trip for CMOs

Is price control by stealth the future for the United States?

FDA approves Janus kinase inhibitors Rinvoq and Cibinqo despite safety concerns

Over $1bn raised in venture capital funding for gene editing in 2021

In Depth

Cutting the carbon footprint of pharma’s supply chain

Uneven supply patterns hinder US rollout of Covid-19 antivirals

How AI could unlock the medical potential of psychedelics

Covid-19 vaccine mixing: could heterologous boosters improve immunity?

Molnupiravir supplies dominate in times of Paxlovid scarcity

In Data

Revealed: pharma leaders in precision, personalised medicine

Asia-Pacific is seeing a hiring boom in pharmaceutical cybersecurity roles

Venture financing deals in pharma rise in H2 2021

Markets and indices

Macro-economic data